Group 1 - Evercore ISI raised the price target on Labcorp (LH) to $305 from $300 while maintaining an Outperform rating on the shares [1] - The firm's survey indicates a positive outlook for preclinical CROs, with rising budgets and declining cancellations [1] - There is stable demand for discovery and toxicology services projected into 2025 and 2026 [1]